- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Head and neck squamous cell carcinoma (HNSCC)
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 1.3MB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 769.8KB)
Pembrolizumab – November 2025
Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - November 2025
Last updated
5 November 2025